Drugs / WAL0921
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05891366 | May 2023 → Jan 2024 | — | Walden Biosciences | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06466135 | Jul 2024 → Mar 2027 expected | IgA glomerulonephritis, diabetic kidney disease, membranous glomerulonephritis, minimal change disease +1 | Walden Biosciences | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-04-15 | Walden Biosciences | Results Walden Biosciences Announces Positive Topline Data from Phase 1+ Clinical Study of WAL0921 in Development for Treatment of Kidney Diseases waldenbiosciences.com ↗
Data from the study showed that WAL0921 was safe, well-tolerated, and demonstrated proof-of-biology through a rapid, dose-dependent reduction in free suPAR levels. |
All press releases naming this drug 6 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WAL0921 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05891366 ↗ |
| Route | Intravenous | “Single intravenous infusion of investigational drug WAL0921” NCT05891366 ↗ |